STANDLOW, NCT03689114: Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy |
|
|
| Active, not recruiting | 4 | 374 | Europe | Low dose carbamazepine, low carbamazepine, Standard dose carbamazepine, Standard carbamazepine, Low dose levetiracetam, Low levetiracetam, Standard dose levetiracetam, Standard levetiracetam, Low dose valproate, Low valproate, Standard dose valproate, Standard valproate, Low dose zonisamide, Low zonisamide, Standard dose zonisamide, Standard zonisamide, Low dose oxcarbazepine, Low oxcarbazepine, Standard dose oxcarbazepine, Standard oxcarbazepine, Low dose topiramate, Low topiramate, Standard dose topiramate, Standard topiramate, Low dose lamotrigine, Low lamotrigine, Standard dose lamotrigine, Standard lamotrigine, Low dose gabapentin, Low gabapentin, Standard dose gabapentin, Standard gabapentin | Mario Negri Institute for Pharmacological Research, Azienda Ospedaliera San Gerardo di Monza, Ministry of Health, Italy | Epilepsies, Partial | 06/24 | 08/24 | | |
| Completed | 2/3 | 164 | Canada, US | Placebo Oral Tablet, AGB101 220 mg tablet | AgeneBio, National Institute on Aging (NIA) | Mild Cognitive Impairment, Prodromal Alzheimer's Disease | 11/22 | 11/22 | | |
NCT05986721: Clinical Trial of AGB101 for Mild Cognitive Impairment |
|
|
| Recruiting | 2 | 60 | US | AGB101, levetiracetam, keppra, Placebo, placebo tablet | AgeneBio | Mild Cognitive Impairment, Prodromal Alzheimer's Disease | 07/28 | 12/28 | | |
NCT02647437: Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia |
|
|
| Recruiting | N/A | 30 | US | Levetiracetam, Keppra, Placebo | University of Colorado, Denver | Schizophrenia | 06/24 | 06/24 | | |
